IQVIA (NYSE:IQV) Given New $319.00 Price Target at Royal Bank Of Canada

IQVIA (NYSE:IQV) had its price target raised by equities research analysts at Royal Bank Of Canada from $247.00 to $319.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada’s price target points to a potential upside of 17.71% from the company’s previous close.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings raised shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday. Barclays restated an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. BMO Capital Markets upped their target price on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research note on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.75.

IQVIA Price Performance

Shares of IQV opened at $271.01 on Tuesday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA has a twelve month low of $154.50 and a twelve month high of $277.40. The stock has a market capitalization of $44.61 billion, a P/E ratio of 33.62, a P/E/G ratio of 2.31 and a beta of 1.18. The company has a 50 day moving average of $250.32 and a 200-day moving average of $203.63.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the firm posted $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts forecast that IQVIA will post 11.56 EPS for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the completion of the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock valued at $3,796,021 in the last 90 days. Corporate insiders own 1.70% of the company’s stock.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently bought and sold shares of the company. QRG Capital Management Inc. boosted its position in shares of IQVIA by 87.7% during the 2nd quarter. QRG Capital Management Inc. now owns 58,407 shares of the medical research company’s stock worth $11,285,000 after acquiring an additional 27,283 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in IQVIA by 3.7% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 4,872 shares of the medical research company’s stock valued at $941,000 after purchasing an additional 174 shares in the last quarter. National Pension Service lifted its stake in IQVIA by 6.6% during the second quarter. National Pension Service now owns 375,973 shares of the medical research company’s stock worth $72,646,000 after purchasing an additional 23,411 shares during the last quarter. WINTON GROUP Ltd acquired a new stake in shares of IQVIA in the 2nd quarter valued at $5,046,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of IQVIA in the 2nd quarter valued at $632,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.